Dr. Sander J. Gothard, M.D.
Family Medicine (Family Medicine Physician)
- Medicare participating
At a glance
- Medical school
- University of Texas Medical School at Houston (1998)
- Years since graduation
- 28
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 319
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1998Medical school: University of Texas Medical School at Houston
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
TX license K1202
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Medical City Plano Plano, TX
- Baylor Scott & White Medical Center Plano Plano, TX
- Texas Health Presbyterian Hospital Plano Plano, TX
Medical groups
- Catalyst Physician Group - Ntx, PLLC (86 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 319
- Services billed
- 2,008
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 496 | 233 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 205 | 205 |
| Established patient office or other outpatient visit, 20-29 minutes | 189 | 127 |
| Annual depression screening, 5 to 15 minutes | 126 | 126 |
| Administration of influenza virus vaccine | 50 | 50 |
| Influenza vaccine split virus, preservative free | 48 | 48 |
| Administration of pneumococcal vaccine | 46 | 46 |
| Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | 46 | 46 |
| Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus and influenza | 43 | 36 |
| Assessment of emotional or behavioral problems | 40 | 21 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 12 companies reported 20 payments worth $419 in total to this clinician.
| Novo Nordisk Inc | $158 |
|---|---|
| Astellas Pharma US Inc | $33.58 |
| Corium, LLC | $30.65 |
| GlaxoSmithKline, LLC. | $29.70 |
| Sanofi-aventis U.S. LLC | $27.10 |
| Bayer HealthCare Pharmaceuticals Inc. | $23.92 |
| Inari Medical, Inc. | $23.37 |
| Exact Sciences Corporation | $22.27 |
| Food and Beverage | $419 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 5 companies. The companies reported $1,111,540 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis
ModernaTX, Inc. · Active, not recruiting · NCT06592794 - A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age
Seqirus USA Inc · Completed · NCT06087640 - A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults
ModernaTX, Inc. · Active, not recruiting · NCT05164094 - The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older
Seqirus USA Inc · Completed · NCT06015282 - A phase iii, open-label, randomized, controlled, multi-country study t
GlaxoSmithKline, LLC. - A phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like part…
AstraZeneca Pharmaceuticals LP - A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients…
Alnylam Pharmaceuticals Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.